Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: Involvement of CD4+ and CD8+ T cells in protection

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7234-7240

  Kim, Tae Yoon ^a   Myoung, Han Jeong ^b   Kim, Ji Hyun ^b   Moon, In Sung ^a   Kim, Tai Gyu ^a   Ahn, Woong Shick ^a   Sin, Jeong Im ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; OLIGODEOXYNUCLEOTIDE; PROTEIN; PROTEIN E7; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

ANIMALS; ANTIBODY SPECIFICITY; CANCER VACCINES; CELL LINE, TRANSFORMED; CPG ISLANDS; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON TYPE II; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TUMOR CELLS, CULTURED; TUMOR VIRUS INFECTIONS;

EID: 0037115506     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Bohle, B., Jahn-Schmid, B., Maurer, D., Kraft, D., and Ebner, C. Oligodeoxynucleotides containing CpG motifs induce IL-12. IL-18 and IFN-γ production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur. J. Immunol., 29: 2344-2353, 1999.
2. Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J., and Krieg, A. M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc. Natl. Acad. Sci. USA, 93: 2879-2883, 1996.
3. Krieg, A. M., Yi, A-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., and Klinman, D. CpG motifs in bacterial DNA trigger direct B cell activation. Nature (Lond.), 374: 546-549, 1995.
4. Ballas, Z. K., Rasmussen, W. L., and Krieg, A. M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol., 157: 1840-1845, 1996.
5. Sparwasser, T., Vabulas, R. M., Villmow, B., Lipford, G. B., and Wagner, H. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur. J. Immunol., 30: 3591-3597, 2000.
6. Sparwasser, T., Koch, E. S., Vabulas, R. M., Heeg, K., Lipford, G. B., Ellwart, J. W., and Wagner, H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol., 28: 2045-2054, 1998.
7. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V., and Harding, C. V. CpG oligonucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med., 186: 1623-1631, 1997.
8. Leclerc, C., Deriaud, E., Rojas, M., and Whalen, R. G. The preferential induction of Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell. Immunol., 179: 97-106, 1997.
9. Klinman, D. M., Yamshchikov, G., and Ishigatsubo, Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol., 158: 3635-3639, 1997.
10. Jakob, T., Walker, P. S., Krieg, A. M., Udey, M. C., and Vogel, J. C. Activation of cutaneous dendritic cells by CpG-containing oligonucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol., 161: 3042-3049, 1998.
11. Roman, M., Martin-Orozco, E., Goodman, J. S., Nguyen, M. D., Sato, Y., Ronaghy, A., Kornbluth, R. S., Richman, D. D., Carson, D. A., and Raz, E. Immunostimulatory DNA sequences function as T helper-1-promoting addjuvants. Nat. Med., 3: 849-854, 1997.
12. Davis, H. L., Weeranta, R., Waldschmidt, T. J., Tygrett, L., Schorr, J., and Krieg, A. M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol., 160: 870-876, 1998.
13. Warren, T. L., Bhatia, S. K., Acosta, A. M., Dahle, C. E., Ratliff, T. L., Krieg, A. M., and Weiner, G. J. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J. Immunol., 165: 6244-6251, 2000.
14. Weiner, G. J., Liu, H-M., Wooldridge, J. E., Dahle, C. E., and Krieg, A. M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA, 94: 10833-10837, 1997.
15. Davis, H. L., McCluskie, M. J., Gerin, J. L., and Purcell, R. H. DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl. Acad. Sci. USA, 93: 7213-7218, 1996.
16. Kline, J. N., Waldschmidt, T. J., Businga, T. R., Lemish, J. E., Weinstock, J. V., Thorne, P. S., and Krieg, A. M. Modulation of airway inflammation against asthma by CpG oligonucleotides in a murine model of asthma. J. Immunol., 160: 2555-2559, 1998.
17. Scott Gallichan, W., Woolstencroft, R. N., Guarasci, T., McCluskie, M. J., Davis, H. L., and Rosenthal, K. L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol., 166: 3451-3457, 2001.
18. zur Hausen, H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virol., 184: 9-13, 1991.
19. Scheffner, M., Munger, K., Bryne, J. C., and Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523-5527, 1991.
20. Werness, B. A., Levine, A. J., and Howley, P. M. Association of HPV type 16 and 18 E6 protein with p53. Science (Wash. DC), 248: 76-79, 1990.
21. Dyson, N., Howley, P. M., Munger, K., and Harlow, E. The human papilomavirus-16 E7 oncoprotein is able to bind the retinoblastoma gene product. Science (Wash. DC), 243: 934-937, 1989.
22. de Gruijl, T. D., Bontkes, H. J., Stukart, M. J., Walboomers, J. M., Remmink, A. J., Verheijen, R. H., Helmerhorst, T. J., Meijer, C. J., and Scheper, R. J. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J. Gen. Virol., 77: 2183-2191, 1996.
23. Fernando, G. J. P., Murray, B., Zhou, J., and Frazer, I. H. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin. Exp. Immunol., 115: 397-403, 1999.
24. Hung, C. F., Cheng, W. F., Hsu, K. F., Chai, C. Y., He, L., Ling, M., and Wu, T. C. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res., 61: 3698-3703, 2001.
25. Lamikanra, A., Pan, Z. K., Isaacs, S. N., Wu, T. C., and Paterson, Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J. Virol., 75: 9654-9664, 2001.
26. Cheng, W. F., Hung, C. F., Hsu, K. F., Chai, C. Y., He, L., Polo, J. M., Slater, L. A., Ling, M., and Wu, T. C. Cancer immunotherapy using sindbis virus replicon particles encoding a VP22-antigen fusion. Hum. Gene Ther., 13: 553-568, 2002.
27. Liu, D. W., Tsao, Y. P., Kung, J. T., Ding, Y. A., Sytwu, H. K., Xiao, X., and Chen, S. L. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol., 74: 2888-2894, 2000.
28. Londono, L. P., Chatfield, S., Tindle, R. W., Herd, K., Gao, X. M., Frazer, I., and Dougan, G. Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen. Vaccine, 14: 545-552, 1996.
29. Feltkamp, M. C., Smits, H. L., Vierboom, M. P., Minnaar, R. P., de Jongh, B. M., Drijfhout, J. W., ter Schegget, J., Melief, C. J., and Kast, W. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol., 23: 2242-2249, 1993.
30. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
31. Sin, J. I., Sung, J. H., Suh, Y. S., Lee, A. H., Chung, J. H., and Sung, Y. C. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: Effect of co-injection with a granulocyte, macrophage-colony stimulating factor gene. Vaccine, 15: 1827-1833, 1997.
32. Sin, J. I., Kim, J., Pachuk, C., Satishchanran, C., and Weiner, D. B. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th-1 type CD4+ T cell-mediated protecetive immunity against herpes simplex virus-2 in vivo. J. Virol., 74: 11173-11180, 2000.
33. Sin, J. I., Kim, J. J., Zhang, D. H., and Weiner, D. B. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Hum. Gene Ther., 12: 1091-1102, 2001.
34. Sin, J. I., Kim, J., Arnold, R. L., Shroff, K. E., McCallus, D., Pachuk, C., McElhiney, S. P., Wolf, M. W., Pompa-de Bruin, S. J., Higgins, T. J., Ciccarelli, R. B., and Weiner, D. B. Interleukin-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1 type CD4+ T cell mediated protective immunity against HSV-2 challenge. J. Immunol., 162: 2912-2921, 1999.
35. Lin, K. Y., Guarnieri, F. G., Staveley-O'Carroll, K. F., Levitsky, H. I., August. J. T., Pardoll, D. M., and Wu, T. C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res., 56: 21-26, 1996.
36. Armstrong, D. J., and Roman, A. The anomalous electrephoretic behavior of the human papillomavirus type 16 E7 protein is due to the high content of the acidic amino acid residues. Biochem. Biophys. Res. Commun., 192: 1380-1387, 1993.
37. Wu, T. C., Guarnieri, F. G., Staveley-O'Carroll, K. F., Viscidi, R. P., Levitsky, H. I., Hedrick. L., Cho, K. R., August, J. T., and Pardoll, D. M. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. USA, 92: 11671-11675, 1995.
38. Finkelman, F. D., Holmes, J., Katona, I. M., Urban, J. F., Beckmann, M. P., Park, L. S., Schooley, K. A., Coffman, R. L., Mosmann, T. R., and Paul, W. E. Lymphokine control of in vivo immunoglobulin isotype selection. Ann. Rev. Immunol., 8: 303-333, 1990.
39. Liu, H-M., Newbrough, S. E., Bhatia, S. K., Dahle, C. E., Krieg, A. M., and Weiner, G. J. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood, 92: 3730-3736, 1998.
40. Krieg, A. M., Love-Homan, L., Yi, A. K., and Harty, J. T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenges. J. Immunol., 161: 2428-2434, 1998.
41. Al-Mariri, A., Tibor, A., Mertens, P., De Bolle. X., Michel, P., Godefroid, J., Walravens, K., and Letesson, J. J. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect. Immun., 69: 4816-4822, 2001.
42. Samuel, C. E. Antiviral actions of interferon: Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology, 183: 1-11, 1991.
43. Smith. P. M., Wolcott. R. M., Chervenak, R., and Jennings, S. R. Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-γ (IFN-γ). Virology, 202: 76-88, 1994.
44. Boehm, U., Klamp, T., Groot, M., and Howard, J. C. Cellular responses to interferon-g. Annu. Rev. Immunol., 15: 749-795, 1997.
45. Yang, Y., Waters, J. B., Fruh, K., and Peterson, P. A. Proteasomes are regulated by interferon γ: Implications for antigen processing. Proc. Natl. Acad. Sci. USA, 89: 4928-4932, 1992.